MPNE at ASCO 2016
Saturday, 4 June 2016
Poster discussion Saturday
POSTER DISCUSSION SESSION
Sat, Jun 04
4:45 PM - 6:00 PM
Summary of the posters presented at ASCO in Melanoma-
1. BRIM7 extended follow-up : Vem plus Cobimetinib
median PFS 13.8 months for Vem plus Cobimetibinb!
median OS was more than 2.5 years
and interestingly enough, there were some l
to complete response, so some patients got a complete response after a considerable time on treatment.
Now the next question will be whether these patients would be generally doing well, or just particular well on targeted therapy.
2. Trametinib plus GSK2141795 in uveal Melanoma
single MEKi (tram) versus combination MEKi with AKT inhibitor, randomised
unfortunately, no difference in PFS, so MEK plus AKT inhibitors does not work better than MEKi alone. Plus: high toxicity- leading to frequent dose reductions.
Question- was the hypothesis correct? Was the pathway inhibition sufficient?
Bad news :-(
3. Cell cycle inhibtion: CDK4 pathway aberration is predominant in acral Melanoma
(more than 80%)
cell and animals models are sensitive to CDK4inhibitors- so this could eventually give additional treatment options to patients with acral Melanoma (Melanoma starting on the hand and feet)
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)